Table 3.
The association of cancer diagnosis to observed and expected cancer incidence (%/year) grouped according to time interval relative to biopsy date
| Time interval (years) | −10 to −5 | −5 to −3 | −3 to −1 | −1 to 0 | 0–1 | 1–3 | 3–5 | 5–10 | −10 to 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Colorectal | Observed | 0.03 | 0.06 | 0.05 | 0.07 | 0.26 | 0.06 | 0.14 | 0.17 | 0.08 |
| Expected | 0.05 | 0.09 | 0.12 | 0.17 | 0.22 | 0.24 | 0.27 | 0.33 | 0.16 | |
| Risk ratio | 0.5 (0,2–1.0) | 0.7 (0.3–1.5) | 0.4 (0.2–0.9) b | 0.4 (0.1–1.1) | 1.2 (0.6–2.1) | 0.2 (0.1–0.5) d | 0.5 (0.2–1.0) | 0.5 (0.3–0.9) c | 0.5 (0.4–0.6) d | |
| Lung | Observed | 0.00 | 0.03 | 0.04 | 0.20 | 0.32 | 0.26 | 0.17 | 0.23 | 0.10 |
| Expected | 0.01 | 0.01 | 0.02 | 0.06 | 0.12 | 0.13 | 0.14 | 0.16 | 0.06 | |
| Risk ratio | 0.7 (0–3.9) | 2.8 (0.6–8.2) | 1.8 (0.5–4.6) | 3.1 (1.6–5.6) c | 2.7 (1.5–4.4) d | 2.0 (1.2–3.1) c | 1.2 (0.6–2.3) | 1.4 (0.9–2.1) | 1.6 (1.3–2.0) d | |
| Melanoma | Observed | 0.01 | 0.03 | 0.01 | 0.04 | 0.02 | 0.07 | 0.07 | 0.08 | 0.03 |
| Expected | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Risk ratio | 0.7 (0.2–2.1) | 1.3 (0.3–3.7) | 0.3 (0–1.8) | 1.1 (0.1–3.9) | 0.6 (0–3.4) | 2.3 (0.8–5.0) | 2.1 (0.6–5.5) | 2.1 (0.9–4.4) | 1.2 (0.8–1.7) | |
| Breasta | Observed | 0.13 | 0.11 | 0.11 | 0.22 | 0.19 | 0.12 | 0.03 | 0.28 | 0.15 |
| Expected | 0.09 | 0.12 | 0.17 | 0.18 | 0.18 | 0.19 | 0.20 | 0.22 | 0.15 | |
| Risk ratio | 1.4 (0.8–2.3) | 0.9 (0.3–2.0) | 0.6 (0.2–1.5) | 1.2 (0.4–2.8) | 1.0 (0.3–2.7) | 0.6 (0.2–1.6) | 0.1 (0–0.8) b | 1.2 (0.7–2.0) | 1.0 (0.7–1.3) | |
| Gynaecologica | Observed | 0.02 | 0.02 | 0.09 | 0.13 | 0.05 | 0.03 | 0.09 | 0.05 | 0.05 |
| Expected | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 | 0.09 | 0.10 | 0.11 | 0.07 | |
| Risk ratio | 0.4 (0.1–1.5) | 0.4 (0–2.5) | 1.4 (0.4–3.6) | 1.7 (0.4–5.1) | 0.5 (0–3.0) | 0.4 (0–2.1) | 1.0 (0.2–2.8) | 0.5 (0.1–1.2) | 0.7 (0.4–1.2) | |
| Prostatea | Observed | 0.04 | 0.08 | 0.12 | 0.49 | 0.74 | 0.22 | 0.20 | 0.27 | 0.19 |
| Expected | 0.04 | 0.09 | 0.15 | 0.17 | 0.18 | 0.20 | 0.22 | 0.27 | 0.14 | |
| Risk ratio | 1.1 (0.5–2.3) | 0.8 (0.3–1.9) | 0.8 (0.4–1.6) | 2.9 (1.7–4.8) d | 4.2 (2.6–6.5) d | 1.1 (0.5–2.0) | 0.9 (0.4–1.9) | 1.0 (0.6–1.6) | 1.3 (1.1–1.7) d | |
| Renal | Observed | 0.01 | 0.02 | 0.03 | 0.29 | 0.16 | 0.03 | 0 | 0.05 | 0.05 |
| Expected | 0.004 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Risk ratio | 2.0 (0.2–7.1) | 2.9 (0.3–10.4) | 3.0 (0.6–8.6) | 21.4 (12.2–34.8) d | 9.2 (4.0–18.2) d | 1.8 (0.4–5.1) | 0 (0–2.4) | 2.3 (0.9–4.7) b | 4.1 (2.9–3.5) d | |
| Bladder | Observed | 0.01 | 0.02 | 0.03 | 0 | 0.02 | 0.05 | 0.05 | 0.09 | 0.03 |
| Expected | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | 0.05 | |
| Risk ratio | 0 .2 (0–0.9 ) b | 0.6 (0.1–2.0) | 0.7 (0.1–1.9) | 0 (0–1.3) | 0.3 (0–1.8) | 0.7 (0.1–2.1) | 0.6 (0.1–1.8) | 0.9 (0.4–1.9) | 0.5 (0.3–0.8) c | |
| Hodgkin lymphoma | Observed | 0 | 0.01 | 0.01 | 0 | 0.02 | 0 | 0.00 | 0.01 | 0.004 |
| Expected | 0.002 | 0.002 | 0.002 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | |
| Risk ratio | 0 (0–6.7) | 3.9 (0.1–21.7) | 3.7 (0.1–20.8) | 0 (0–25.2) | 6.3 (0.2–34.9) | 0 (0–13.9) | 0 (0–15.8) | 3.2 (0.1–17.9) | 1.6 (0.4–4.2) | |
| Non-Hodgkin Lymphoma | Observed | 0.01 | 0.02 | 0.03 | 0.16 | 0.17 | 0.03 | 0.06 | 0.06 | 0.04 |
| Expected | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
| Risk ratio | 1.4 (0.3–4.2) | 1.5 (0.2–5.5) | 1.8 (0.4–5.3) | 8.1 (3.7–15.4) d | 7.3 (3.1–14.3) d | 1.1 (0.1–4.0) | 2.3 (0.6–5.9) | 1.9 (0.7–4.1) | 2.5 (1.8–3.5) d | |
| Myeloma | Observed | 0.004 | 0.01 | 0.02 | 0.23 | 0.44 | 0.02 | 0 | 0.02 | 0.05 |
| Expected | 0.001 | 0.003 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Risk ratio | 3.1 (0.1–17.4) | 3.0 (0.1–16.8) | 3.6 (0.4–12.9) | 32.6 (17.3–55.7) d | 49.4 (31.0–74.8) d | 2.2 (0.3–7.8) | 0 (0–4.4) | 1.6 (0.3–4.8) | 8.6 (6.3–11.6) d | |
| Leukaemia | Observed | 0.01 | 0.03 | 0.06 | 0.09 | 0.17 | 0.03 | 0.05 | 0.06 | 0.04 |
| Expected | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.06 | 0.03 | |
| Risk ratio | 0.8 (0.1–2.8) | 1.7 (0.4–5.0) | 2.9 (1.2–6.0) b | 3.1 (1.0–7.3) b | 3.9 (1.7–7.7) c | 0.7 (0.1–2.5) | 1.0 (0.2–2.8) | 0.9 (0.4–1.9) | 1.5 (1.0–2.0) b | |
| Skin (non-melanoma) | Observed | 0.08 | 0.14 | 0.22 | 0.21 | 0.14 | 0.54 | 0.64 | 0.74 | 0.27 |
| Expected | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.03 | |
| Risk ratio | 7.8 (4.9–11.7) c | 7.4 (4.2–12.0) d | 8.6 (5.5–12.6) d | 6.4 (3.3–11.1) d | 3.6 (1.5–7.5) c | 12.1 (8.7–16.3) d | 12.1 (8.5–16.7) d | 10.9 (8.5–13.8) d | 8.7 (7.6–9.9) d | |
| Unclassified | Observed | 0.04 | 0.05 | 0.07 | 0.22 | 0.53 | 0.33 | 0.25 | 0.43 | 0.17 |
| Expected | 0.04 | 0.05 | 0.07 | 0.11 | 0.19 | 0.20 | 0.22 | 0.25 | 0.12 | |
| Risk ratio | 1.1 (0.6–2.0) | 1.1 (0.4–2.4) | 1.0 (0.4–2.0) | 1.9 (1.0–3.3) b | 2.8 (1.9–4.1) d | 1.6 (1.1–2.4) b | 1.1 (0.7–1.8) | 1.7 (1.2–2.3) c | 1.5 (1.2–1.7) d | |
| Any not skin | Observed | 0.20 | 0.35 | 0.46 | 1.63 | 2.37 | 0.99 | 0.77 | 1.06 | 0.71 |
| Expected | 0.19 | 0.30 | 0.41 | 0.55 | 0.80 | 0.86 | 0.95 | 1.10 | 0.55 | |
| Risk ratio | 1.0 (0.8–1.3) | 1.2 (0.8–1.6) | 1.1 (0.8–1.5) | 2.9 (2.6–3.4) d | 3.0 (2.5–3.6) d | 1.1 (0.9–1.4) | 0.8 (0.6–1.1) | 1.0 (0.8–1.1) | 1.3 (1.2–1.4) d | |
Significant risk ratios in bold type
a: relevant sex only. b:< 0.05; c:< 0.01; d:< 0.001